Herombopag Olamine Tablets are a novel oral small molecule thrombopoietin receptor agonist indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have had an inadequate response to immunosuppressive therapy (IST).
This document is a technical review report for the marketing authorization of Herombopag Olamine Tablets (海曲泊帕乙醇胺片) by Jiangsu Hengrui Medicine Co., Ltd. The drug is a small molecule TPO-R agonist intended for the treatment of adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy. The review was conducted by the Center for Drug Evaluation of China's National Medical Products Administration.
The report covers basic information about the applicant and drug, verification and compliance evaluation, and comprehensive review opinions on pharmacology, clinical pharmacology, efficacy, safety, and risk-benefit assessment. The application received conditional approval and priority review status, with final processing opinions including technical conclusions and post-marketing requirements. This manual is written in Chinese.
| Specifications | 2.5 mg, 3.75 mg, 5 mg (calculated as C25H22N4O5) |
|---|---|
| Indication | Adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy (IST) |
| Recommended initial dosage | 7.5 mg once daily |
| Maximum dosage | 15 mg once daily |
| Chemical name | (Z)-5-(2-羟基-3-(2-(3-甲基-5-氧代-1-(5,6,7,8-四氢萘-2-基)-1H-吡唑-4(5H)-亚基)肼基)苯基)呋喃-2-羧酸乙醇胺盐(1∶2) |
| Molecular formula | C25H22N4O5•2C2H7NO |
| Molecular weight | 580.64 |
It is indicated for adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy (IST).
The tablets are available in 2.5 mg, 3.75 mg, and 5 mg strengths (calculated as C25H22N4O5).
The recommended initial dose is 7.5 mg once daily.